James W. Rocco

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Associations Between Preexisting Depression and Anxiety and Postoperative Outcomes Among Medicare Beneficiaries Undergoing Head and Neck Cancer Surgery

  Head & Neck · 2026-05-04

• Abstract 3617: Immunogenomic alterations driving premalignant lesions to invasive lesions of the head and neck

  Cancer Research · 2026-04-03

• Abstract 3871: Molecular correlates of response and survival in a phase II trial of weekly carboplatin/paclitaxel plus cemiplimab (wCP+C) in advanced/metastatic mucosal head and neck squamous cell carcinoma (a/mHNSCC).

  Cancer Research · 2026-04-03

• Determinants of Circulating Tumor HPV DNA in Surgically Treated Oropharyngeal Cancer

  JAMA Otolaryngology–Head & Neck Surgery · 2026-04-02

• Long-Term Outcomes of Weekly Cisplatin Versus Carboplatin and Paclitaxel for Head and Neck Cancer

  JCO oncology advances. · 2026-01-01

• Building on ECOG-ACRIN E3311 to Strengthen Interpretation of Swallowing Outcomes

  JCO oncology advances. · 2026-01-01

• Delays in Radiation Therapy for Head and Neck Cancer: The Role of Pre‐Radiation Dental Clearance

  Otolaryngology · 2025-12-26 · 2 citations

• Pembrolizumab in Head and Neck Cancer—Promise and Price

  JAMA Otolaryngology–Head & Neck Surgery · 2025-12-18

• Circulating Human Papillomavirus DNA—Liquid Biopsy in Head and Neck Cancers

  Journal of Medical Virology · 2025-11-28 · 1 citations

• Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer

  Clinical Cancer Research · 2025-10-21 · 2 citations

• Medicaid Expansion Status and Receipt of Palliative Care in Stage IV Oral Cavity Cancer

  OTO Open · 2025-10-01

• Association of health insurance types and out-of-pocket expenses with clinical outcomes among patients with head and neck cancer.

  JCO Oncology Practice · 2025-10-01

• Association of percutaneous endoscopic gastrostomy (PEG) tube with unplanned hospitalization and clinical outcomes among patients with head and neck cancer.

  JCO Oncology Practice · 2025-10-01

• High-Risk HPV Testing in Head and Neck Carcinoma: Key Updates from the 2025 College of American Pathologists Guideline

  Head and Neck Pathology · 2025-09-29 · 3 citations

• Abstract A143: Association of treatment delays with health insurance and clinical outcomes among patients with head and neck cancer receiving definitive treatments

  Cancer Epidemiology Biomarkers & Prevention · 2025-09-18

• Evaluation of Neutrophil to Lymphocyte Ratio in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With a Combination of Cetuximab and Nivolumab in a Phase II Clinical Trial

  American Journal of Clinical Oncology · 2025-09-04

• 1351P Phase II study on the treatment of recurrent/metastatic (R/M) head and neck squamous cell cancer (HNSCC) using low-dose weekly carboplatin and paclitaxel metronomic chemotherapy (MCT) combined with cemiplimab

  Annals of Oncology · 2025-09-01

• Salvage Surgery Followed by IORT for Locoregionally Persistent or Recurrent Head and Neck Cancer

  International Journal of Radiation Oncology*Biology*Physics · 2025-09-01

• Association of Systemic Inflammation Response Index with Outcomes for Head and Neck Cancer

  International Journal of Radiation Oncology*Biology*Physics · 2025-09-01

• 1360P Retrospective analysis of concurrent weekly carboplatin, paclitaxel, and cetuximab (PTC) as second-line therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (2L R/M HNSCC) following progression on immunotherapy

  Annals of Oncology · 2025-09-01